Momenta Pharmaceuticals (Nasdaq:MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory strategy in the United States for M923, Momenta’s proposed biosimilar to HUMIRA. As quoted in the press release: Momenta had previously guided that it planned to file … Continued